Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Four Patent Applications Related to RNAi: May 15, 2008

Title: Inhibitor Oligonucleotides and Their Use for Specific Repression of a Gene
Number: 7,371,735
Filed: Nov. 8, 2002 PCT Filed: Nov. 8, 2002
Lead Inventor: Annick Harel-Bellan, French National Center for Scientific Research
The patent, its abstract states, claims “a method of treating a disease resulting from the expression of a harmful gene. … The method includes the step of administering a therapeutically effective amount of a pharmaceutical composition having at least one double-stranded oligonucleotide including two complementary oligonucleotide sequences forming a hybrid. Each oligonucleotide sequence comprises at one of their 3' or 5' ends one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid,” the abstract adds. “One of the oligonucleotide sequences is substantially complementary to a target sequence belonging to a DNA or messenger RNA molecule of a gene coding a mutated or non-mutated androgen receptor.”

Title: Sustained-Release Intraocular Drug-Delivery Systems Comprising a Water-Soluble Therapeutic Agent and a Release Modifier
Number: 20080107694
Filed: Nov. 3, 2006
Lead Inventor: John Trogden, Allergan
The patent application, according to its abstract, claims “a biocompatible, sustained-release intraocular drug-delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained-release intraocular drug-delivery system can be used to treat an ocular condition.”
The application specifically claims the delivery of an siRNA using the system.

Title: Compositions and Methods for Inhibiting Expression of IKK-B Gene
Number: 20080108584
Filed: May 21, 2007
Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals
According to the patent application’s abstract, the invention related to “a double-stranded ribonucleic acid for inhibiting the expression of the IKK-B gene comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition, and methods for inhibiting the expression of the IKK-B gene in a cell.”

Title: Lipophilic Conjugated iRNA Agents
Number: 20080108801
Filed: Aug. 3, 2007
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
“The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose,” the patent application’s abstract states. “The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.”

Title: Functional and Hyperfunctional siRNA Directed Against Bcl-2
Number: 20080108802, 20080108803
Filed: Oct. 16 & 19, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent applications’ abstracts state. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing Bcl-2.”

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.